4.3 Review

Early antifungal intervention strategies in ICU patients

期刊

CURRENT OPINION IN CRITICAL CARE
卷 16, 期 5, 页码 465-469

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCC.0b013e32833e0487

关键词

antifungals; early therapy; empirical treatment; ICU; invasive candidiasis

资金

  1. Astellas
  2. Merck
  3. Pfizer
  4. Associates of Cape Cod

向作者/读者索取更多资源

Purpose of review Despite progress in the understanding of the pathophysiology of invasive candidiasis, and the development of new classes of well tolerated antifungals, invasive candidiasis remains a disease difficult to diagnose, and associated with significant morbidity and mortality. Early antifungal treatment may be useful in selected groups of patients who remain difficult to identify prospectively. The purpose of this review is to summarize the recent development of risk-identification strategies targeting early identification of ICU patients susceptible to benefit from preemptive or empirical antifungal treatment. Recent findings Combinations of different risk factors are useful in identifying high-risk patients. Among the many risk factors predisposing to invasive candidiasis, colonization has been identified as one of the most important. In contrast to prospective surveillance of the dynamics of colonization (colonization index), integration of clinical colonization status in risk scores models significantly improve their accuracy in identifying patients at risk of invasive candidiasis. Summary To date, despite limited prospective validation, clinical models targeted at early identification of patients at risk to develop invasive candidiasis represent a major advance in the management of patients at risk of invasive candidiasis. Moreover, large clinical studies using such risk scores or predictive rules are underway.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据